Response of retinal vessels and retrobulbar hemodynamics to intravitreal anti-VEGF treatment in eyes with branch retinal vein occlusion

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 6, 2011, Pages 3046-3050

  Sacu, Stefan ^a   Pemp, Berthold ^a   Weigert, Günther ^a   Matt, Gerlinde ^a   Garhofer, Gerhard ^a   Pruente, Christian ^a   Schmetterer, Leopold ^a   Schmidt Erfurth, Ursula ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

ACUTE DISEASE; AGED; ANALYZER; ARTICLE; BLOOD FLOW VELOCITY; BRANCH RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CLINICAL TRIAL; COLOR ULTRASOUND FLOWMETRY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FLOW RATE; FOLLOW UP; HEMODYNAMICS; HUMAN; MALE; PRIORITY JOURNAL; RETINA ARTERY; RETINA BLOOD VESSEL; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; UNSPECIFIED SIDE EFFECT; VASOCONSTRICTION; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BLOOD FLOW VELOCITY; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; ORBIT; REGIONAL BLOOD FLOW; RETINAL VEIN OCCLUSION; RETINAL VESSELS; RETREATMENT; ULTRASONOGRAPHY, DOPPLER, COLOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASODILATION; VISUAL ACUITY;

EID: 79955944274     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-5842     Document Type: Article

References (36)

1. Greer DV, Constable IJ, Cooper RL. Macular oedema and retinal branch vein occlusion. Aust J Ophthalmol. 1980;8:207-209.
2. Gutman FA, Zegarra H. The natural course of temporal retinal branch vein occlusion. Trans Am Acad Ophthalmol Otolaryngol. 1974;78:OP178-192.
3. Michels RG, Gass JD. The natural course of retinal branch vein obstruction. Trans Am Acad Ophthalmol Otolaryngol. 1974;78: OP166-177.
4. Frangieh GT, Green WR, Barraquer-Somers E, Finkelstein D. Histopathologic study of nine branch retinal vein occlusions. Arch Ophthalmol. 1982;100:1132-1140.
5. Hayreh SS. Retinal vein occlusion. Indian J Ophthalmol. 1994;42: 109-132.
6. Remky A, Arend O, Bertram B. Thrombus and branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 1997;235:802.
7. Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res. 2005;24:493-519.
8. Miller SD. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1985;99:218-219.
9. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984;98:271-282.
10. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res. 2008;33: 111-131.
11. Krepler K, Ergun E, Sacu S, et al. Intravitreal triamcinolone acetonide in patients with macular oedema due to branch retinal vein occlusion: a pilot study. Acta Ophthalmol Scand. 2005;83:600-604.
12. Scott IU, Ip MS, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009;127:1115-1128.
13. Campochiaro PA, Hafiz G, Shah SM, et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther. 2008;16:791-799.
14. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117: 1102-1112.
15. Maar N, Luksch A, Graebe A, et al. Effect of laser photocoagulation on the retinal vessel diameter in branch and macular vein occlusion. Arch Ophthalmol. 2004;122:987-991.
16. Stefansson E. The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmol Scand. 2001;79:435-440.
17. Stefansson E, Pedersen DB, Jensen PK, et al. Optic nerve oxygenation. Prog Retin Eye Res. 2005;24:307-332.
18. Strenn K, Menapace R, Rainer G, Findl O, Wolzt M, Schmetterer L. Reproducibility and sensitivity of scanning laser Doppler flowmetry during graded changes in PO2. Br J Ophthalmol. 1997;81: 360-364.
19. Garhofer G, Bek T, Boehm AG, et al. Use of the retinal vessel analyzer in ocular blood flow research. Acta Ophthalmol. 2010; 88:717-722.
20. Polak K, Dorner GT, Kiss B, et al. Evaluation of the Zeiss retinal vessel analyser. Br J Ophthalmol. 2000;84:1285-1290.
21. Guthoff RF, Berger RW, Winkler P, Helmke K, Chumbley LC. Doppler ultrasonography of the ophthalmic and central retinal vessels. Arch Ophthalmol. 1991;109:532-536.
22. Lieb WE, Cohen SM, Merton DA, Shields JA, Mitchell DG, Goldberg BB. Color Doppler imaging of the eye and orbit. Technique and normal vascular anatomy. Arch Ophthalmol. 1991;109:527-531.
23. Mendrinos E, Mangioris G, Papadopoulou D, Donati G, Pournaras C. One year results of the effect of intravitreal ranibizumab on the retinal arteriolar diameter in patients with neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009 Sep 24 [Epub ahead of print].
24. Papadopoulou DN, Mendrinos E, Mangioris G, Donati G, Pournaras CJ. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration. Ophthalmology. 2009;116:1755-1761.
25. Ferrara N, Gerber HP. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol. 2001;106:148-156.
26. Tilton RG, Chang KC, LeJeune WS, Stephan CC, Brock TA, Williamson JR. Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF. Invest Ophthalmol Vis Sci. 1999;40:689-696.
27. Uhlmann S, Friedrichs U, Eichler W, Hoffmann S, Wiedemann P. Direct measurement of VEGF-induced nitric oxide production by choroidal endothelial cells. Microvasc Res. 2001;62:179-189.
28. Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of antivascular endothelial growth factor agents. Am J Ophthalmol. 2008;146:930-934.
29. Yokoyama K, Choshi T, Kimoto K, Shinoda K, Nakatsuka K. Retinal circulatory disturbances following intracameral injection of bevacizumab for neovascular glaucoma. Acta Ophthalmol. 2008; 86:927-928.
30. Kriechbaum K, Prager F, Geitzenauer W, et al. Association of retinal sensitivity and morphology during antiangiogenic treatment of retinal vein occlusion over one year. Ophthalmology. 2009;116:2415-2421.
31. Wroblewski JJ, Wells JA, III, Gonzales CR. Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion. Am J Ophthalmol. 2010;149:147-154.
32. Wu L, Arevalo JF, Roca JA, et al. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan- American Collaborative Retina Study Group at 6 months of followup. Retina. 2008;28:212-219.
33. Hoeh AE, Ach T, Schaal KB, Scheuerle AF, Dithmar S. Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2009;247:1635-1641.
34. Riva CE, Grunwald JE, Sinclair SH, Petrig BL. Blood velocity and volumetric flow rate in human retinal vessels. Invest Ophthalmol Vis Sci. 1985;26:1124-1132.
35. Werkmeister RM, Dragostinoff N, Pircher M, et al. Bidirectional Doppler Fourier-domain optical coherence tomography for measurement of absolute flow velocities in human retinal vessels. Opt Lett. 2008;33:2967-2969.
36. Polska E, Kircher K, Ehrlich P, Vecsei P, Schmetterer L. RI in central retinal artery as assessed by CDI does not correspond to retinal vascular resistance. Am J Physiol Heart Circ Physiol. 2001; 280:H1442-1447.